Sunday, August 01, 2021 5:31:28 PM
The lens you're applying is incorrect.
The SEC or DOJ do not typically inform the persons under subpoena who else is being investigated, how its proceeding, what is next, when is it over etc.
Whether a company initiates the complaint (requests someone look at something), is involved in an investigation that initiates by someone else's request or is the direct subject of the investigation - they are not privy to anything other than what the investigators ask of them during various written and oral interview sessions.
Second - they are under strict orders to divulge nothing other than what is absolutely required by law for shareholder notification and information sharing. Nothing else can be divulged as it would place the investigation at risk of being compromised and inform potential suspects or others of events - providing lead time to escape/prepare or market manipulate.
In my very basic involvement through the SEC interview I mentioned as a shareholder of a company under investigation - I was warned very sternly on a recorded call with multiple investigators. When the charges were brought forward and docket/supporting evidence was shared - the government had included hundreds of references to traced calls, texts, digital actions, timing and cascade/sequence events that showed collusion and more - with dates that were months before and months after my interview. To be clear - these were not related to me in any way - but to people involved in the criminal activities and those who were dumb enough to chatter even when warned not to. They have access to emails accounts, mobile and land line and a thousand other ways to trace whether anyone (such as one like me - interviewed regarding the company) contacted anyone they are not supposed to or said/shared anything they are not supposed to share.
Nader and CytoDyn can say NOTHING (whether they are being looked at as the culprit, victim or anything in between).
Don't read too much into this. It will become visible when they are ready to make it so.
The SEC or DOJ do not typically inform the persons under subpoena who else is being investigated, how its proceeding, what is next, when is it over etc.
Whether a company initiates the complaint (requests someone look at something), is involved in an investigation that initiates by someone else's request or is the direct subject of the investigation - they are not privy to anything other than what the investigators ask of them during various written and oral interview sessions.
Second - they are under strict orders to divulge nothing other than what is absolutely required by law for shareholder notification and information sharing. Nothing else can be divulged as it would place the investigation at risk of being compromised and inform potential suspects or others of events - providing lead time to escape/prepare or market manipulate.
In my very basic involvement through the SEC interview I mentioned as a shareholder of a company under investigation - I was warned very sternly on a recorded call with multiple investigators. When the charges were brought forward and docket/supporting evidence was shared - the government had included hundreds of references to traced calls, texts, digital actions, timing and cascade/sequence events that showed collusion and more - with dates that were months before and months after my interview. To be clear - these were not related to me in any way - but to people involved in the criminal activities and those who were dumb enough to chatter even when warned not to. They have access to emails accounts, mobile and land line and a thousand other ways to trace whether anyone (such as one like me - interviewed regarding the company) contacted anyone they are not supposed to or said/shared anything they are not supposed to share.
Nader and CytoDyn can say NOTHING (whether they are being looked at as the culprit, victim or anything in between).
Don't read too much into this. It will become visible when they are ready to make it so.
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
